|
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN …
Business Wire (press release) The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA™ (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). As part of the company’s overall … |
Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN …MarketWatch (press release)… (prolonged-release fampridine tablets). The company will also present results from the investigational trials of its late-stage MS pipeline,…
 Irish Times |
New drugs give real hope to MS sufferers
Irish Times Ms Kelly’s condition is a long way removed from that of Marie Fleming and more typical of the kinds of conditions encountered by MS sufferers. Another drug which is currently part of a clinical trial in Ireland is Daclizumab made by Abbvie, an offshoot … |
Zortress Indication Expanded for Liver Transplant PatientsMonthly Prescribing ReferenceZortress is currently indicated for organ rejection prophylaxis in renal transplant patients with low-moderate immunologic risk, in combination with basiliximab indu…
|
Doctors’ Column: New drug may help with MS symptoms
ReporterNews.com However, researchers at the National Institutes of Health have discovered that the drug daclizumab appears to tone down the autoimmune response in MS patients, providing hope for those trying to overcome the obstacles of living with MS. MS is an … |
|
How Safe Is Abbvie’s Dividend?
Seeking Alpha Daclizumab, a next generation biologic, developed with Biogen for multiple sclerosis. Results from the first of two pivotal trials demonstrated strong efficacy in reducing relapse rates and disability performance. The second pivotal trial is fully … |
|
Multiple Sklerose: Neue Therapiemöglichkeiten und Schwangerschaft
ptext.de (Pressemitteilung) Frank Schmitz, Facharzt für Neurologie und Psychiatrie aus Ladenburg, stellt insbesondere die Fumarsäure (BG 12), Alemtuzumab, Daclizumab, Teriflunomid sowie neue S1P-Modulatoren vor. Da die MS-Diagnose häufig Menschen zwischen dem 20. und … |
|
More Smart Savings From ASHP Meeting
Pharmacy Practice News That means that, in many cases, recipients require higher levels of induction agents, such as antithymocyte globulin (ATG) and basiliximab (Siumulect, Novartis) than those who receive nonmarginal kidneys. “When you combine the high cost of these drugs … |
|
신장 이식 환자에서 mTOR 억제제 기반의 면역 억제 요법
청년의사 피험자 전원은 스테로이드와 함께 유도 요법으로 basiliximab을 투여 받았으며, 연구진은 두 군의 BPAR, 이식편 소실, 사망, 추적관찰 소실, 신기능(eGFR), 이상반응 발생률을 비교하였다. 이식 환자의 연령, 성별, HLA-부적합, 투석 여부, 동반 질환은 두 군 간 유 … |
Postcardiac transplant survival in the current era in patients receiving …The Journal of Thoracic and Cardiovascular SurgeryIf the patient had renal dysfunction (glomerular filtration rate <30 mL/min/1.73 m2) for 3 days after transplantation, an i…